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Abstract
Hematopoietic stem cells (HSC) are rare, multipotent cells capable of generating all specialized cells of the blood system.
Appropriate regulation of HSC quiescence is thought to be crucial to maintain their lifelong function; however, the
molecular pathways controlling stem cell quiescence remain poorly characterized. Likewise, the molecular events driving
leukemogenesis remain elusive. In this study, we compare the gene expression profiles of steady-state bone marrow HSC to
non-self-renewing multipotent progenitors; to HSC treated with mobilizing drugs that expand the HSC pool and induce
egress from the marrow; and to leukemic HSC in a mouse model of chronic myelogenous leukemia. By intersecting the
resulting lists of differentially regulated genes we identify a subset of molecules that are downregulated in all three
circumstances, and thus may be particularly important for the maintenance and function of normal, quiescent HSC. These
results identify potential key regulators of HSC and give insights into the clinically important processes of HSC mobilization
for transplantation and leukemic development from cancer stem cells.
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Introduction
Hematopoietic stem cells (HSC) are rare, multipotent, self-
renewing precursor cells capable of generating each and every
specialized cell of the blood system. Precise regulation of HSC
proliferation and cell fate decisions is necessary to maintain
ongoing production of mature blood cells throughout adult life
and for rapid, regenerative responses to hematologic injury.
Several lines of evidence indicate the importance of active
maintenance of HSC stem cell function. The regulation of HSC
quiescence in the bone marrow (BM) niche is of particular
importance [1,2]. Several recently identified genes that perturb
HSC quiescence also disrupt stem cell maintenance and
homeostatic blood cell production. Many of these encode
transcription factors or cell cycle regulators that directly modulate
the proliferative activity of HSC. Others encode soluble mediators,
produced by niche cells that act extrinsically to activate HSC
proliferation. Together, these data suggest that precise control of
cell division is crucial for appropriate stem cell behavior and that
the proliferative activity of HSC is normally restricted by both
HSC intrinsic factors and extrinsic factors produced in the HSC
niche. Elucidating the molecular pathways that maintain HSC
quiescence will thus enable directed manipulation of HSC
function endogenously and in the context of hematopoietic cell
transplantation.
Although the tightly regulated equilibrium between HSC
quiescence and proliferation is clearly important for long-term
maintenance of stem cell function, some physiologic functions of
HSC require short-term perturbation of this balance. For
example, during stem cell differentiation, which is required for
normal blood cell production, HSC exit quiescence to generate
more mature multi- and oligopotent progenitor cells, with
concurrent loss of self-renewal potential and gain in proliferative
activity [3]. In addition, stem cells can be ‘‘mobilized’’ in response
to hematopoietic stress, rapidly undergoing expansion and
migration to repopulate the peripheral hematopoietic compart-
ments. Stem cell function is also perturbed during leukemogenesis,
in which oncogenic transformation derails the normal state of
HSC to promote proliferation, metastasis to extramedullary sites,
and the production of abnormal blast cells. Significantly, while
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associated with increased proliferation and loss of self-renewal
activity [4–6], mobilization and transformation of HSC induces
proliferation without loss of self-renewal potential, demonstrating
that a highly proliferative state does not preclude maintenance of
long-term self-renewal. A complete understanding of the complex
regulatory networks that govern HSC function remains an
essential, but elusive, goal.
Elucidation of stem cell regulatory mechanisms in many
systems has been advanced greatly in recent years by the
application of genome-wide profiling approaches to characterize
gene regulatory networks in purified stem cell populations. To
specifically investigate the mechanisms by which normal HSC are
maintained, we have examined how the expression profile of
normal, quiescent HSC changes under three different scenarios:
normal differentiation into multipotent progenitors (MPP);
cytokine-induced expansion and mobilization; and leukemic
transformation. When considered individually, these gene
expression profiles provide significant molecular insights to the
regulation of each of these specific processes. Moreover, when
considered collectively, these data identify alterations in gene
expression that are common to all three conditions assayed. This
meta-analysis defines a signature profile of normal, quiescent
stem cells present in the BM of mice and reveals novel molecular
pathways that are commonly altered when HSC are uprooted
from their normal quiescent niche. Given that HSC are the
essential functional units in BM transplantation, the identification
of factors that regulate their maintenance and function will likely
improve treatments for hematodeficiency and hematopoietic
cancers. Thus, these studies provide insights into the normal
differentiation and mobilization of HSC, and the molecular
mechanisms by which these processes are usurped or dysregulat-
ed during oncogenesis and cancer metastasis.
Results
Cytokine-Induced Mobilization of HSC
In adult mice and humans, the majority of HSC are found in
the BM, although HSC are also constitutively present at low levels
in the circulation [7,8]. The frequency of HSC in the blood can be
significantly increased through the use of mobilizing agents,
including cytotoxic drugs and/or cytokines, which act to both
drive HSC proliferation and to induce HSC migration from the
BM into the bloodstream. In particular, treatment of mice with a
combination of the chemotoxin cyclophosphamide (Cy) - which
kills mainly proliferating hematopoietic progenitors and very few
of the G0 HSC - plus the cytokine granulocyte-colony stimulating
factor (G-CSF or G) induces a rapid and reproducible expansion
and migration of BM HSC [9–11]. Following administration of Cy
+ 2 daily doses of G, the BM HSC population (referred to
hereafter as mobHSC) expands dramatically, reaching ,10–12
times the size of the HSC compartment in normal animals [9].
Expansion of HSC in this early phase of mobilization occurs only
in the BM [11], and appears to be associated with an increase in
HSC self-renewal and an accelerated rate of HSC division, as
measured by incorporation into newly synthesized DNA of the
thymidine analog bromodeoxyuridine (BrdU) [3]. While BM HSC
of unmanipulated animals are largely quiescent (,10% of cells in
S-G2/M phases of the cell cycle), up to 35% of mobHSC exhibit
.2n DNA content, and ,85% of these cells incorporate BrdU
after only 12 hours of labeling [3]. After day +2, HSC frequencies
in the BM decline as HSC migrate from the marrow and begin to
appear in significant numbers in the blood and spleen of mobilized
animals [9,12].
To identify specific molecular mediators of the proliferative and
migratory responses of HSC to Cy/G-induced hematopoietic
stress, we used DNA microarray technology to identify changes in
gene expression associated with HSC mobilization. This analysis
yielded a dataset comprised of 2,611 targets exhibiting differential
expression (Figure 1); 2,461 clones (representing 1,670 individual
genes) were significantly downregulated in mobHSC as compared
to untreated BM HSC (Supplemental Table S1), while only
150 clones (representing 97 individual genes) (Supplemental
Table S2) were significantly upregulated in response to Cy/G
treatment. This bias towards reduced gene expression upon
mobilization may suggest that downregulation of genes actively
maintaining HSC quiescence is an important mechanism of
cytokine-induced HSC expansion.
Functional classification of genes differentially expressed by
non-mobilized versus mobHSC revealed that ,half of these
encode unknown genes or uncharacterized EST sequences. Gene
Ontology (GO) analysis [13] was performed to functionally classify
the known genes, and revealed significant enrichment among up-
regulated genes of cell cycle regulators, translation and RNA
processing factors, and genes involved in basic cell metabolic
processes. These findings are consistent with the robust activation
of proliferation and uniform exit from quiescence induced in HSC
by Cy/G treatment. Among the significantly down-regulated
genes, a sizable proportion encoded transcription factors, signaling
proteins, and cell cycle associated proteins, largely inhibitors of cell
cycle progression (Supplemental Table S1).
Figure 1. Significance Analysis of Microarray (SAM) plots. Pair-wise comparison of gene expression during HSC differentiation, mobilization,
and leukemic transformation. Features colored green or red represent genes up- or downregulated, respectively, in each comparison.
doi:10.1371/journal.pone.0008785.g001
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Leukemia is an aberrant hematopoietic process that can be
initiated and sustained by rare leukemic stem cells (LSC) that drive
the formation and growth of tumors [14–17]. Recent evidence
indicates that LSC can emerge either from transformed HSC
[17,18] or from transformed progenitor cells that have re-acquired
the stem cell property of self-renewal [15]. In one model,
preleukemic progression of a myeloproliferative disorder occurs
in the only self-renewing cells of the myeloid lineage, HSC, but
emerges from these clones when self-renewal is not shut down [or
re-emerges] when these preleukemic or chronic phase leukemic
HSC develop multipotent or oligolineage progenitors at acute or
blast crisis phases of the disease [19]. Developing interventions
that specifically target LSC is an appealing strategy for improving
the specificity and efficiency of cancer treatment [20]. Such
targeting will require understanding of how LSC escape normal
regulatory mechanisms to become malignant. Myeloid malignan-
cies provide an excellent opportunity for addressing these
fundamental questions at the cellular and molecular level as
relevant LSC populations have been identified and can be
distinguished and isolated apart from other cells in the tumor [21].
Mice lacking the AP-1 transcription factor JunB in hematopoi-
etic cells develop a myeloproliferative disorder (MPD) that
accurately reproduces important clinical aspects of human
leukemias including chronic myelogenous leukemia (CML) and
chronic myelomonocytic leukemia (CMML). We have identified
the LSC population in these mice as arising from the HSC
compartment [17,18,22]. Loss of JunB function in HSC causes an
aberrant stem cell expansion leading to MPD development and
eventually frank leukemia. Inactivation of junB endows HSC with
proliferative and survival advantages, two key properties necessary
for HSC transformation into LSC.
To identify molecular mediators of leukemic transformation in
junB-deficient HSC, we performed gene expression microarray
analysis. Because gene expression profiles of LSC may differ
depending on the stage of the disease, we investigated the LSC
population of each leukemic mouse separately and selected for
analysis only those mice exhibiting advanced MPD but no blast
crisis progression. This strategy was designed to uncover genes
involved in the initial steps of HSC transformation caused by loss
of JunB expression, which in turn mediates the early phase of
leukemia development.
RNA was isolated and amplified from 4,000–8,000 double-
sorted HSC from the BM of individual junB-deficient mice. Target
transcripts significantly up- or down-regulated were identified by
Statistical Analysis of Microarrays (SAM) [23] of six independent
arrays according to the criteria described previously [24]. These
analyses detected 1,203 targets, representing 958 individual genes,
that were significantly downregulated in junB-deficient HSC
(Figure 1 and Supplemental Table S3). In contrast, only 26
target cDNAs, representing 23 individual genes, were upregulated
in the same population (Supplemental Table S4). This bias
towards reduced gene expression suggests that JunB acts primarily
as a transcriptional activator in HSC and suggests that
downregulation of genes actively maintaining HSC function is
an important prerequisite for their leukemic transformation.
Meta-Analysis Reveals a Normal HSC Signature
We previously employed gene expression profiling to study
changes in gene regulation associated with the differentiation of
self-renewing HSC to MPP [24], uncovering many novel pathways
that regulate normal HSC function and specify HSC differenti-
ation. Thus, together with the mobilization and leukemogenesis
arrays described above, we have performed 3 pairwise compar-
isons to identify changes of gene expression associated with the
differentiation, mobilization, or transformation of purified HSC
([24]; Figure 1). A heatmap representation of these comparisons
is presented in Figure 2. These three distinct processes have in
common some characteristic cellular responses, for example the
exit of HSC from quiescence and entry of these cells into cycle. To
determine whether common molecular pathways mediate such
shared HSC responses during differentiation, mobilization, and
leukemic transformation, we next performed a meta-analysis of the
differentially regulated genes from these three pairwise compar-
isons. We searched for significant two-way and three-way overlaps
among the differentially expressed gene lists identified in the HSC
vs. MPP, mobilized (Mob) vs. non-mobilized (nonMob), and
leukemic (LSC) vs. non-leukemic (nonLSC) HSC datasets
(Figure 3). The significance of all two-way and three-way
intersections was estimated using the hypergeometric distribution.
Several of these intersections yielded no or few overlapping genes.
In particular, given that both LSC (‘‘LSC’’, green, solid,) and
mobHSC (‘‘Mob’’, blue, solid) exhibit substantial expansion of the
stem cell population, we were surprised to find no overlap of
significantly enriched genes in these populations. This result
suggests that self-renewing divisions of mobilized HSC induced in
response to Cy/G treatment are driven by pathways distinct from
those that drive leukemic expansion upon loss of JunB.
In contrast, intersection of genelists describing targets enriched
in MPP relative to HSC, and in non-mobilized and non-leukemic
HSC, did yield a short list of 32 clones, representing 30 unique
targets. This set represents genes whose expression is increased as
HSC differentiate to MPP, but reduced when HSC are mobilized
Figure 2. Heatmap representation of differential gene expres-
sion. Each of the 18 columns represents a pairwise comparison. Rows
represent individual genes. Note that ‘‘nonLSC’’ and ‘‘nonMob’’ are the
normal HSC counterparts to LSC and mobilized HSC.
doi:10.1371/journal.pone.0008785.g002
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proteins with transcriptional regulatory activity, including Esr1,
Fos, Foxp1, Iep5, Laf4, and several zinc finger containing proteins:
Zfp148, Zfp36, and Zfp469. A common property of MPP,
mobilized HSC and LSC is their enhanced proliferative activity;
however, unlike mobilized HSC and LSC, MPP harbor little or no
self-renewal activity. Thus, the genes included in this set may
represent those whose expression in proliferating cells is incom-
patible with self-renewal, such that they must be down-regulated
to support expansion of self-renewing HSC (mobilization) or
LSC (transformation), and are increased in MPP to promote
differentiation.
Importantly, intersecting genes selectively enriched in non-
mobilized and non-leukemic HSC with genes enriched in HSC
when compared to MPP yielded 129 clones representing 93
individual genes (Figure 3 and Supplemental Table S5). The
93 unique genes in this intersection thus are expressed by
‘‘normal’’, quiescent HSC, and are downregulated during
differentiation, mobilization and leukemogenesis. This overlapping
dataset is of particular interest as it likely includes genes that are
crucial for the steady-state maintenance and regulation of a
normal, slowly proliferating HSC.
Genes Enriched in Normal HSC
Using quantitative RT-PCR (qRT-PCR), we validated the
differential expression of several of the 93 genes from the 3-way
intersect described above using new, independently generated
samples (Figure 4). All genes in the HSC/MPP and HSC/
mobHSC data sets showed the same trend by qRT-PCR as seen in
the array analysis. While this concordance of data was also true for
the vast majority of genes in the HSC vs. LSC comparison, some
genes identified as downregulated by array analysis did not show
significant downregulation when analyzed by qRT-PCR in an
independent set of sorted samples. This variability likely relates to
subtle differences in the precise stage of MPD at which individual
junB-deficient animals were sacrificed, reflecting mouse-to-mouse
variability in disease progression. Future studies to generate a
more refined time course of differential gene expression in junB-
deficient HSC may identify the order in which genes are up- and
downregulated during leukemogenesis, and their interdependence
or importance for disease initiation versus progression.
We broadly categorized the 93 HSC ‘‘signature’’ genes based on
GO analysis (Figure 5) and subcellular location. Enriched
expression was observed for several genes encoding extracellular
proteins, including biglycan, transglutaminase2, follistatin-like1,
angiopoietin1 and procollagen4a2. Expression of several of these
in ‘‘normal’’ HSC likely has significant implications for regulation
of HSC quiescence. For example, biglycan is an extracellular
matrix (ECM) proteoglycan that binds TGF-beta, collagen, and
other ECM components. Interestingly, biglycan-deficient mice
develop age-associated osteopenia thought to arise from defects in
the maintenance and metabolic activity of osteogenic precursor
Figure 3. Venn diagram representation of differential gene expression. Lists of differentially expressed clones in each pairwise comparison
were compared to identify clones that are shared or unique to different HSC fates. The numbers represent the number of up- or downregulated
clones in each pairwise comparison and the number of clones shared between comparisons.
doi:10.1371/journal.pone.0008785.g003
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to TGFbeta among osteolineage cells [25]. As TGF-beta has been
reported as a negative regulator of HSC number, down-regulation
of biglycan among differentiating, mobilizing and transformed
HSC may insulate them from TGF-beta activity, thus facilitating
their enhanced proliferative activity. Similarly, binding of
angiopoietin 1 (Angpt1), a secreted cytokine, to its receptor Tie2
on HSC is reported to enhance HSC quiescence and to modulate
expression of adhesion molecules implicated in HSC mobilization
and retention in the BM [26]. Interestingly, although previous
studies have suggested that osteoblasts are the primary producers
of Angpt1 in BM, our gene expression data suggest that HSC
quiescence can also be modulated by autocrine effects.
Several membrane proteins, including Syndecan2, Edg1,
calsyntenin1, Map17, Phemx, Ryk, Itm2a, Jam1 and Jam3,
Robo4, Cish, Protein C receptor (PRCR), Prion protein, Mllt4
and Ica1 were enriched in the HSC signature. Several of these
receptors are involved in cell migration or location in other
systems. Edg1 encodes a receptor for sphingosine 1-phosphate
(S1P). S1P recently has been characterized as a unique bimodal
regulator of cell migration in the thymus and lymphatic system
[27], an important determinant of plasma cell homing from
lymph nodes to BM [28], and a key regulator of the physiologic
recirculation of HSC and progenitor cells [29]. Thus, downreg-
ulation of S1P receptor on HSC may facilitate their egress from
the BM niche. Likewise, Jam2 is a leukocyte migration receptor
that mediates heterotypic cell-cell interactions with integrin
alpha(4)beta(1) (VLA-4), an important receptor in the BM
homing and mobilization of HSC [30]. Jam1 and Jam3 were
recently shown to be reliable markers for HSC [31,32]. Thus, the
Jam family of adhesion molecules are likely important for HSC
retention in the niche. Cish is a membrane protein involved in
the downregulation of cytokine responsiveness, potentially acting
as a growth inhibitor. Notably, the genomic region encoding Cish
is frequently deleted in lung and kidney tumors, implicating this
gene in tumor progression and suggesting that its loss in LSC
might potentiate leukemic transformation of HSC [33]. Ryk is a
tyrosine-kinase-like receptor and a coreceptor for the Wnt
signaling protein, previously implicated in the maintenance of
mouse HSC [34,35]. Ryk was shown recently to play roles in
neural stem cell differentiation by Wnt-induced translocation to
the nucleus [36]. Finally, Robo4 is a homolog of the brain-
specific Roundabout receptors that bind the secreted Slit ligands
and play roles in axon guidance, while PRCR selectively marks
HSC [37] and Prion protein has been implicated in HSC self-
renewal [38].
Figure 4. Quantitative RT-PCR of HSC, MPP, D+2 mobilized HSC and LSC. The relative level of expression of genes identified by microarray
analysis as downregulated upon HSC differentation, mobilization and leukemic transformation. Normal HSC levels were set to 100. Grey bars, HSC;
red, MPP; blue, mobilized HSC; green, LSC.
doi:10.1371/journal.pone.0008785.g004
Figure 5. Gene ontology classification of genes selectively expressed by normal, quiescent HSC.
doi:10.1371/journal.pone.0008785.g005
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signature of genes involved in basic metabolic processes, including
members of the glycogen phosphorylase (Pygl), aldehyde dehy-
drogenase (Aldh1a7), guanylate cyclase 1 (Gucy1a3), lactate
dehydrogenase (Ldh2), and cytochrome P450 (Cyp2j6) families.
Enrichment of these genes may reflect a differential requirement
for certain metabolic effectors in the transition from a largely
quiescent and metabolically inactive HSC to a highly proliferative
and metabolically active cell upon differentiation, mobilization or
transformation.
Nuclear proteins enriched among HSC signature genes include
cell cycle regulators such as Cdkn1c, Necdin, and Rbbp9, and
transcription factors such as Creb3l2, Mllt3, Pbx1, Prdm16,
Smarca2 and Zfp467. Creb3l2 belongs to the basic leucine-zipper
family of transcription factors and was identified as a balanced
translocation fusion partner in low-grade fibromyxoid sarcoma
[39]. Ndrg2 is a candidate tumor suppressor gene on chromosome
14q that is inactivated during meningioma progression. Ndrg2
expression is induced by WT1, a transcriptional regulator
frequently expressed in leukemias [40]. Mllt3 (AF9) plays roles
in hematopoietic differentiation into megakaryocyte and erythroid
lineages [41] and as a translocation partner with Mll causes
leukemia via a leukemic stem cell mechanism. Thus, Mllt3 plays
roles in normal cell growth and maintenance and in oncogenesis
[42,43]. Pbx1 cooperates with Hox proteins and has well-
established roles in hematopoiesis [44–46]. Intriguingly, it was
recently suggested that Pbx1 promotes HSC quiescence and self-
renewal [47]. A short form of Prdm16 (MEL1) has been shown to
block G-CSF-induced myeloid differentiation [48] and thus may
help to maintain the undifferentiated state of HSC, whereas
Zfp467 augments and transactivates Stat3 signaling. Nrip1 and
Rex3 were proposed to be diagnostic markers of different forms of
leukemias [49]. Vilar et. al. suggested that Rex3 links cell surface
receptor signaling to the cell cycle and neuronal differentiation by
binding the neurotrophin receptor [50]; HSC-selective expression
indicates that Rex3 could play similar roles in regulating
proliferation and differentiation among hematopoietic precursors.
Smarca2, a SWI/SNF-related regulator of chromatin also known
as Brm, plays important roles in transcriptional processes via
regulation of chromatin modifications and structure. Smarca2 also
interacts with TopBP1, a protein involved in DNA replication and
the DNA damage checkpoint to promote cell survival [51].
Smarca2 has been linked to inhibition of cell proliferation through
interactions with cyclin D3 [52]. In agreement with the differential
expression in our data sets, Muchardt et al suggested previously
that increased levels of Smarca2 promote the withdrawal of the
cell from the cell cycle [53].
Collectively, the genes discussed above define a molecular
signature associated with the steady-state quiescent status of HSC,
and suggest common targets whose perturbation can lead to
enhanced cell proliferation in the context of either differentiation,
stem cell expansion, or transformation.
Comparison to Previous Findings
To place the 93 genes in the context of other expression studies
in HSC, we compared the similarity between our set and the genes
upregulated in six previous HSC studies [54–59]. Specifically, we
assessed the overlap between the genes identified as upregulated in
each of the six studies and our 93 genes and estimated the
hypergeometric p-value associated with each comparison. In spite
of differences in the identity of the comparison cell type, as well as
platforms and assessment of significance of differential regulation,
we found a significant overlap between our data set and all other
studies (Figure 6 and Table 1). Several genes, notably biglycan
(Bgn), protein C receptor (Procr), retinol binding protein (Rbp1),
and T-cell specific GTPase (Tgtp) were upregulated in HSC in six
out of seven studies.
Transcriptional Regulators of HSC-Specific Genes
To identify potential master regulators of genes selectively
expressed in normal HSC, we performed sequence analysis of the
genomic regions upstream of the 93 genes in the common
intersect. We searched for both known transcription factor binding
sites using the Transfac database (http://www.cbil.upenn.edu/
cgi-bin/tess/tess?RQ=NBqt) and for enrichment of novel se-
quence motifs. The abundance of these sequences in the 3way
intersection was compared to both the genome-wide input dataset
and to the mouse genome. This analysis identified two sequence
motifs enriched with statistical significance in the HSC-selected
upstream regions (Figure 7). Intriguingly, these sequences may be
bound by as of yet unidentified transcriptional regulators, as they
do not contain sequence motifs recognized as binding sites for
known transcription factors. In addition, we identified binding sites
for 467 known transcription factors and sites for 8 of these were
significantly enriched in the HSC dataset (Table 2). Literature
searches revealed that all 8 transcription factors have been
implicated in hematopoiesis. In particular, Evi1 is an oncogenic
transcription factor in myeloid leukemias, and may regulate
normal hematopoiesis by interacting with transcription factors in
the Gata family [60,61]. Deletion of the ubiquitously expressed
basic leucine zipper transcription factor AFT4 leads to severe
anemia [62]. The interferon response gene IRF1 may act as a
tumor suppressor by regulating the differentiation and prolifera-
tion of myeloid cells via the Stat pathway [63–66]. Nf1 is a tumor
suppressor that regulates normal hematopoiesis. Mutations in or
Figure 6. Comparison between the findings in our study and
six other reports on HSC gene expression. The 93 genes
selectively expressed in normal HSC are indicated in the left column.
Additional columns represent the same 93 genes in each study, named
below the respective column. Black indicates that the gene was
upregulated in HSC; white indicates that the gene was not upregulated;
gray indicates that the gene was not tested.
doi:10.1371/journal.pone.0008785.g006
Hematopoietic Stem Cell Genes
PLoS ONE | www.plosone.org 6 January 2010 | Volume 5 | Issue 1 | e8785deletion of Nf1 leads to myeloproliferative disorders [67,68]. NF-Y
may play roles in the control of HSC self-renewal by inducing the
expression of Hoxb4 [69], a known positive regulator of HSC self-
renewal [12,70] as well as other genes involved in HSC self-
renewal [71]. NF-Y also has been shown to regulate histone
methylation and may function as both an activator and repressor
of transcription [72]. Finally, the Ikaros proteins are well
characterized in hematopoiesis [73]. Altered ik2, ik4 and ik6
transcripts have recently been identified in Philadelphia chromo-
some-positive acute lymphoblastic leukemia (Iacobucci 2008),
demonstrating that Ikaros and Ikaros target genes play important
roles in leukemogenesis.
It is intriguing to note that the transcription factors we identified
in this metaanalysis play important roles in hematopoiesis. It will
be of interest to determine the comprehensive set of target genes
for these transcription factors in HSC to further build a molecular
portrait of the complex networks of genes that regulate normal
HSC function.
Discussion
Gene expression data from highly purified HSC at steady-state
compared to non-self-renewing, multipotent progeny, to mobi-
lized HSC, and to leukemic HSC provide an intriguing set of
novel target molecules that are commonly induced or repressed
as HSC differentiate, expand and mobilize, and undergo
leukemic transformation. Each of the pair-wise datasets provide
important insights into these specific individual processes at the
genome-wide level, and identify new targets to enable specific
manipulation of HSC in desired directions. Comparative analysis
between datasets identified numerous genes specific for each of
the processes, as well as mechanisms or families of downregulated
genes common to HSC transition into either of the three fates. In
addition to identifying specific molecular regulators and potential
targets for manipulation, these datasets also provide insights into
how gene expression changes are coordinated at a genome-wide
level.
Increased Understanding of Known and Novel Stem Cell
Regulators
As the HSC is one of few stem cells that can be isolated to
homogeneity, has proven multipotentiality at the single-cell level
in vivo, and produces numerous well-characterized and function-
ally distinct progeny, the hematopoietic system represents a
unique opportunity to define the critical molecular regulators of
stem cell function and activity. Importantly, the analyses
performed in this study predicted a number of molecules known
to regulate HSC function. For example, we found that the
transcription factor Egr1 was highly significantly downregulated
in mobilized HSC (Supplemental Table S1). Indeed, it was
recently shown that Egr1 regulates HSC migration and location
[74], as would be expected from its differential expression
described here. Likewise, the adhesion molecule Esam1, identi-
fied in the HSC vs MPP analysis, is a highly selective HSC
marker [75,76]. Although it is not surprising that these and
multiple other known regulators of HSC function were identified,
this concordance of data support the validity of our approaches
and suggests that the numerous novel genes discovered here will
play important roles in the regulation of HSC function under
Table 1. Significance of overlap between our study and six other HSC gene expression studies.
Comparison datasets Genes in common
Max number of genes that could
have been identified
Significance of overlap
(-log10 p-value)
Kiel 35 (89) 89/93 19.4166
Ramalho-Santos 39 (60) 60/93 15.2799
Chambers 18 (89) 89/93 13.6617
Akashi 24 (83) 83/93 12.4116
Venezia 9 (60) 60/93 8.3054
Ivanova 13 (89) 89/93 3.0312
doi:10.1371/journal.pone.0008785.t001
Figure 7. Putative transcription factor binding motifs enriched
in upstream regulatory regions of genes selectively expressed
by normal, quiescent HSC.
doi:10.1371/journal.pone.0008785.g007
Table 2. Transcription factors with binding sites enriched in
the upstream region of genes expressed selectively in HSC.
Evi-1 ecotropic viral integration site 1
ATF4 Activating transcription factor 4
IRF-1 interferon regulatory factor 1
NF-1 neurofibromatosis 1
Ik-2 ikaros 2
c-Myc/Max cellular myelocytomatosis oncogene
NF-Y nuclear transcription factor-Y
MAZ MYC-associated zinc finger protein
doi:10.1371/journal.pone.0008785.t002
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the differentially expressed genes encode unknown genes or
uncharacterized EST sequences, illustrating the fact that a
substantial portion of the transcriptome of HSC remains
unexplored. Indeed, GO analysis indicates that the largest
category of transcripts selective for normal HSC fall in the
‘‘unknown’’ categories in cellular location and molecular function
(Figure 5). Thus, this report opens new avenues of investigation
at the molecular level that will contribute to a more complete
understanding of HSC function.
By performing meta-analysis of differentially expressed gene
sets we defined a unique expression profile highly selective for
quiescent HSC. These ‘‘HSC signature genes’’ likely include
active regulators of controlled self-renewing divisions and
interactions with the microenvironment that function to actively
suppress differentiation, proliferation, and transformation. In
support of this premise, many genes selective for normal HSC
h a v eb e e ns h o w nt of u n c t i o ni ng r o w t hs u p p r e s s i o na n dt o
prevent leukemic transformation. As in the individual pair-wise
comparisons, this analysis revealed a combination of novel genes
and molecules with known roles in HSC function. Further
characterization of known and novel genes will be critical to
enhance strategies for preventing and controlling leukemias,
as well as optimizing conditions for HSC expansion and
mobilization.
Transcriptional Control of HSC Function
It is intriguing to note that all of the transcription factors
identified by the DNA sequence analysis as enriched among HSC
signature genes have known roles in hematopoiesis. This fact
underscores the value of this analysis and suggests that identifying
the factors binding to the novel DNA binding motifs described in
Figure 7 will be fruitful for understanding transcriptional
regulation in HSC. In addition, the demonstration that binding
sites for known transcriptional regulators are enriched in normal
HSC will shed light on the mechanisms of action of these factors.
Further analysis may indeed uncover how these factors converge
on critical target genes and explain functional redundancy or
synergism. Recent technical advances also makes it possible to
assess enzymatic chromatin modifications at sites of interest [77].
Combinatorial control to amplify or counteract transcriptional
signals likely balances critical decisions such as proliferation versus
quiescence or self-renewal versus differentiation. Pursuing the
mechanisms of master regulators promises to be a rewarding
endeavor for understanding the complexities of HSC function.
Self-Renewal vs. Proliferation in the Control of Stem Cell
Activity
While self-renewal capacity is attenuated as HSC differentiate
into MPP, self-renewing divisions increase upon mobilization and
in leukemic HSC. The existence of selective groups of up- and
downregulated genes in these scenarios supports the supposition
that distinct molecular pathways function to signal self-renewal in
different contexts. This finding is consistent with our original
hypothesis that ‘‘induced’’ HSC self-renewal, as in the context of
hematological injury mimicked by mobilization or in response to
oncogenic signals, engages an at least partially distinct group of
regulatory and signaling proteins as compared to HSC self-
renewal under homeostatic conditions. These molecular signa-
tures are defined by the genes and pathways described above.
The data of this report brings us closer to the complete
understanding of co- and antiregulation of functional entities
necessary to fully appreciate the function of HSC in steady-state
and regenerative hematopoiesis, and to pinpoint targets of
oncogenic transformation.
Materials and Methods
Mice
All experiments were performed using young adult (8–12 weeks
old) C57BL/Ka-Thy1.1 or JunB-deficient mice on C57Bl6
background. Cy/G treatment was performed as in (Passegue
2005). Mice null for JunB were described previously [22]. All mice
were maintained in Stanford University’s Research Animal
Facility in accordance with Stanford University guidelines.
Flow Cytometry
Antibody staining and cell sorting were performed as previously
described [3,5,24]. Hematopoietic cell populations were derived
from bone marrow isolated from murine femurs and tibias, unless
otherwise noted. Surface marker phenotypes are provided in
Table 3. Typically, cells were isolated by incubation with
unconjugated lineage antibodies (CD3, CD4, CD5, CD8, B220,
Gr1, Mac1, and Ter119), followed by goat anti-rat Tricolor
(Cy5PE; Invitrogen), and c-kit-APC, Sca1-TxR, Flk2-PE
(eBioscience) and Thy1.1-FITC. Antibodies were purified and
conjugated by standard procedures in the Weissman laboratory,
unless purchased commercially as stated above. Functional
assessment of these populations have been performed in multiple
studies [3–6,8,9,11,17,18,74,76,78–81].
cDNA Array Hybridization
Sample processing was performed as described previously [24].
Briefly, RNA was isolated and amplified from HSC double-sorted
by FACS from the BM of pools of untreated or day +2 Cy/G-
treated C57BL/6-Ka/Thy1.1 mice (50,000–100,000 cells); or
from the BM of individual control or junB-deficient mice
diagnosed with a pre-leukemic MPD (6,000–13,000 cells). RNA
was amplified, dye-labeled with Cy3 or Cy5 and hybridized to
custom spotted cDNA arrays [24] made available through the
Stanford Microarray Core Facility (Stanford University) and
containing 42,025 cDNAs and expressed sequence tags (ESTs)
from a wide variety of tissue- and developmental stage-specific
libraries, including a library made from BM-subtracted HSC
cDNA [82] and a selection of hand-picked genes involved in
development and hematopoiesis [24]. To obtain accurate and
reliable transcription profiles, we performed pairwise competitive
hybridizations in three independent experiments, each with a ‘‘dye
swap’’, so that each comparison was performed 6 times. Slides
were scanned and gridded, and the resulting data files were
submitted to the Stanford Microarray Database (http://genome-
www.stanford.edu/microarray) to assign identity to each spot and
to normalize Cy3/Cy5 relative intensities for each slide. To
identify differentially expressed genes, we employed stringent
criteria of reproducibility, as in [24], requiring a particular spot to
be present in at least 5 out of the 6 pairwise comparisons. Features
passing this criterion were analyzed for statistically significant
differences using Significance Analysis of Microarrays (SAM,
http://www-stat.stanford.edu/,tibs/SAM/) [23]. Significantly
differentially regulated genes were defined by SAM at a false
discovery rate of 10%. Microarray data reported in this
manuscript is described in accordance with MIAME guidelines.
Quantitative RT-PCR
qRT-PCR was performed as described previously [5]. Primer
sequences can be obtained upon request.
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Microarrays
For each of the 40,681 unique clones, we obtained the
nucleotide sequence in NCBI’s mouse EST sequence database
downloaded from ftp://ftp.ncbi.nih.gov/genbank/gbest. We iden-
tified the predicted gene target for each clone by searching for the
best-matching transcript matching the clone. We used BLAST
[83] to compare each clone’s nucleotide sequence to all transcripts
contained in release 7 of the mouse KnownGenes track from the
UCSC Genome Browser’s database. We associated each clone
with the NCBI EntrezGene identifier of the best-matching gene.
We found EST sequences for 34,838 (86%) of the clones on the
microarrays, of which we could identify best-matching genes for
32,402 (93%). These clones mapped to 12,903 unique EntrezGene
identifiers. Thus, each gene was represented by 2.5 clones on
average.
Identifying Significant 3-Way Overlaps
A series of microarray analyses produces a set of clone lists, {C1,
C2,…C L}, where each Ci contains a list of clone identifiers
corresponding to the probes found to be significantly up- or down-
regulated under condition i. Each clone identifier in Ci was
mapped to its corresponding EntrezGene identifier as described
above, and a non-redundant set of genes Gi was produced by
removing any duplicate EntrezGene identifiers. We searched for
statistically significant overlaps between any two combinations of
gene lists Gi and Gj. We calculated a binary overlap score Bij, such
that the probability of an observed overlap or better would occur
by chance is given by the hypergeometric distribution:
Bij~1{
X Oij{1
k~0
Gj
       
k
 !
U jj { Gj
       
Gi jj {k
 !
U jj
Gi jj
  
where |A| is the number of genes in list A, Oij is the number of
overlapping EntrezGene identifiers in Gi and Gj, i.e. (|Gi>Gj|),
and U is the set of all genes with detectable levels of expression on
the microarrays used in our study. A gene was considered
detectable if it had one or more clones that were detectable. A
clone was considered detectable if it had expression levels above
background in at least five out of six replicate hybridizations in at
least one of the microarray data sets.
We calculated binary overlap scores between all pairwise gene
lists. We then search for significant three-way overlaps which are
defined as a set of three gene lists, Gi,G j,G k such that all three
binary overlap scores, Bij, Bik, Bjk are significant. More formally, we
compute a trinary overlap indicator Tij, based on all two-way
intersections with the corresponding original gene lists:
Tijk~ Bijwa
  
\ Bikwa ðÞ \ Bjkwa
  
where a is the significance level (in this study we used a=0.001).
Tijk evaluates to true if all pairs of overlaps are significant at the a
level.
Comparison to Previous Gene Expression Studies
For each study in Figure 6 and Table 1, we mapped the
probes identified as upregulated in the hematopoietic stem cell
population to Entrez Gene. In order to perform a fair comparison
between the studies, we restricted the evaluation to only the genes
that were commonly tested between each specific pair of studies.
This step reduced the total number of genes that could have been
identified as significant from the original upregulated sets. The p-
value was assessed based on the hypergeometric distribution and is
presented in –log10 space (Table 1).
Supporting Information
Table S1 Array features downregulated in day +2 mobilized
HSC compared to HSC at steady-state.
Found at: doi:10.1371/journal.pone.0008785.s001 (0.38 MB
XLS)
Table S2 Array features upregulated in day +2 mobilized HSC
compared to HSC at steady-state.
Found at: doi:10.1371/journal.pone.0008785.s002 (0.04 MB
XLS)
Table S3 Array features downregulated in HSC from the BM of
JunB-deficient mice (LSC) compared to HSC from wt mice.
Found at: doi:10.1371/journal.pone.0008785.s003 (0.19 MB
XLS)
Table S4 Array features upregulated in HSC from the BM of
JunB-deficient mice (LSC) compared to HSC from wt mice.
Found at: doi:10.1371/journal.pone.0008785.s004 (0.02 MB
XLS)
Table S5 Genes enriched in normal, steady-state BM HSC from
wt mice compared to MPP, LSC, and mobilized HSC.
Found at: doi:10.1371/journal.pone.0008785.s005 (0.05 MB
XLS)
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Table 3. Immunophenotyping strategies used to identify stem cells in this study.
Population Immunophenotype References
HSC ckit
+Thy1.1
loLineage marker
2Sca-1
+Flk2
2 (KTLSF
2) Cao, 2004; Christensen, 2001; Forsberg, 2006; Forsberg, 2005; Min,
2008; Ooi, 2009; Passegue, 2005
MPP ckit
+Thy1.1
2Lineage marker
2Sca-1
+Flk2
+(KT
2LSF
+) Cao, 2004; Christensen, 2001; Forsberg, 2006; Forsberg, 2005; Min,
2008; Ooi, 2009; Passegue, 2005
MobHSC/nonMob ckit
+Thy1.1
loLineage marker
2Sca-1
+ (KTLS) Morrison, 1997a; Morrison, 1997b; Morrison, 1994; Wright, 2001;
Passegue, 2005
LSC/nonLSC ckit
+Lineage marker
2Sca-1
+Flk2
2 (KLSF) Passegue, 2004; Santaguida, 2009
doi:10.1371/journal.pone.0008785.t003
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